ALL Clinical Trials in Guangzhou, Guangdong
132 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 132 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+1 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Lung Cancer, Nonsmall Cell
Sun Yat-sen University80 enrolled1 locationNCT06426511
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 3
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Metastatic Breast CancerLocally Advanced Breast Cancer
Shandong Suncadia Medicine Co., Ltd.240 enrolled2 locationsNCT07024173
Recruiting
Phase 2Phase 3
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd254 enrolled22 locationsNCT05860465
Recruiting
Phase 2
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Non-small Cell Lung Cancer
Dizal Pharmaceuticals90 enrolled4 locationsNCT06295432
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Non-small Cell Lung CancerCardiovascular Complication
Sun Yat-sen University524 enrolled1 locationNCT04980716
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2Phase 3
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd374 enrolled9 locationsNCT05744687
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.98 enrolled1 locationNCT06114511
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Phase 3
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.500 enrolled1 locationNCT06671379
Recruiting
Phase 2
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Not Applicable
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
Small Cell Lung Cancer Limited Stage
Zhejiang Cancer Hospital220 enrolled2 locationsNCT05651802
Recruiting
Phase 2
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.110 enrolled2 locationsNCT05351788